Resource Center
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Contact UsLog InLog Out
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Equity Research
Research Reports
Vertex Pharmaceutials, Inc.
Vertex Pharmaceutials, Inc.
Reports
Vertex Pharmaceuticals Reports Strong Second Quarter 2025 Earnings but Stock Slides After VX-993 Clinical Failure
August 8, 2025
KAREN STERLING, PhD, CFA
Download Report
Vertex Pharmaceuticals Reports First Quarter 2025 Earnings
May 7, 2025
KAREN STERLING, PhD, CFA
Download Report
Vertex Pharmaceuticals Announces Strong Performance for Its Cystic Fibrosis Treatments, Mixed Results for Type 1 Diabetes Programs
April 9, 2025
KAREN STERLING, PhD, CFA
Download Report
Vertex Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Earnings
February 14, 2025
KAREN STERLING, PhD, CFA
Download Report
Vertex Pharmaceuticals Announces FDA Approval of JOURNAVXTM (Suzetrigine) for Adults with Moderate to Severe Acute Pain
February 4, 2025
KAREN STERLING, PhD, CFA
Download Report
Vertex Pharmaceuticals Announces Two FDA Approvals in Cystic Fibrosis and Potentially Troubling Phase 2 Results in Chronic Pain
December 23, 2024
KAREN STERLING, PhD, CFA
Download Report
Vertex Pharmaceuticals Provides CASGEVY Program Update at ASH
December 12, 2024
KAREN STERLING, PhD, CFA
Download Report
Vertex Pharmaceuticals Reports Third Quarter 2024 Earnings
November 7, 2024
KAREN STERLING, PhD, CFA
Download Report
Vertex Pharmaceuticals Reports Second Quarter 2024 Earnings
August 5, 2024
KAREN STERLING, PhD, CFA
Download Report
Biotech Company Known for Cutting-Edge Science Is Expanding Beyond Cystic Fibrosis
July 8, 2024
KAREN STERLING, PhD, CFA
Download Report
Securities offered through Kingswood Capital Partners, LLC Member FINRA/SIPC. Advisory services offered through Kingswood Wealth Advisors an SEC registered investment advisor.
Kingswood USNews & MediaAbout UsLinkedInContact Us